Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemia

Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemia

Abstract: Hydroxyurea is the primary disease-modifying medication for sickle cell anemia (SCA), but its long-term effects, particularly how these effects change over time, are not well understood. This study aimed to quantify the effects of hydroxyurea on clinical and laboratory outcomes in children...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul George, Grace Kalmus, Peter A. Lane, Wilbur Lam, Joseph Lipscomb, David Howard
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S247395292500237X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items